Share this article
Share this article
SAN FRANCISCO, March 3, 2021 /PRNewswire/ Blue Note Therapeutics, Inc., today announced the closing of a Series A financing round of $26.25 million. Proceeds will allow the company to scale the organization and fund near-term clinical trials of its lead prescription digital therapeutic (PDT), which will potentially improve the treatment of cancer. The capital will also support the development of Blue Note s pipeline assets. The Series A financing was led by JAZZ Venture Partners and joined by Summer VC.
Blue Note Therapeutics is dedicated to serving patients suffering from cancer-related distress. Working closely with leading cancer research centers and patient communities, Blue Note is developing clinically validated medical devices designed to improve overall cancer outcomes. These products will help address the specific psychosocial needs of oncology patients and may reduce comorbidities such as anxiety, depression, and fear of cancer re
Published: Jan 08, 2021
SAN FRANCISCO, Jan. 8, 2021 /PRNewswire/ Nearly all cancer patients face fear, anxiety, and uncertainty following diagnosis and treatment. Cancer-related distress can impact a patient s emotional and physical well-being, which for many has been further compounded by the COVID-19 pandemic. Founded by a team of biotech veterans, Blue Note Therapeutics, Inc., is leveraging deep scientific and clinical expertise, neuroscience, and digital innovation to make mental health care available to any cancer patient at any time. In 2020, the company launched
COVID Cancer Care, a digital program intended to help adults with cancer cope with stress and anxiety related to the COVID-19 pandemic.